Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Roche has received FDA approval for a label expansion of its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients with HR–positive, HER2-ultralow metastatic ...

Roche announced that the US Food and Drug Administration (FDA) has approved a label expansion for the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now ...

Today, the FDA granted a label expansion approval for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, a companion diagnostic, to identify patients with HR-positive ...

The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay. Additionally, the American Society for Clinical Pathology has guidelines for testing for HER2. Support for the ...

Roche announced the US Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test.

the VENTANA HER2/neu (4B5) IUO (investigational use only) Assay system, according to an algorithm adapted from the 2018 American Society of Clinical Oncology–College of American Pathologists ...

and Her2/Neu-LAMP DNA vaccine, both of which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). This proprietary lysosomal targeting technology results in ...